Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Memphasys Ltd ( (AU:MEM) ) has provided an update.
Memphasys Limited has announced an extension of the maturity date for its $3 million Convertible Notes, with support from Peters Investments Pty Ltd, from June 30, 2025, to December 31, 2025. This extension reflects continued investor confidence and provides Memphasys with additional financial flexibility to further its operations and strategic goals in the reproductive biotechnology sector.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) specializes in reproductive biotechnology for high-value commercial applications. The company develops reproductive biotechnology products, including medical devices, in vitro diagnostics, and proprietary media. Its flagship product, the Felix™ System, uses patented bio separation technology to enhance human artificial reproduction by selecting the most viable sperm cells.
Average Trading Volume: 10,181,599
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$11.51M
For an in-depth examination of MEM stock, go to TipRanks’ Stock Analysis page.